Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus
Objectives To evaluate the safety, tolerability, pharmacokinetics (PK), biomarker response and efficacy of E6742 in a phase I/II study in patients with systemic lupus erythematosus (SLE).Methods Two sequential cohorts of patients with SLE were enrolled and randomised to 12 weeks of two times per day...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-09-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/10/3/e004701.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!